• ILC Therapeutics has secured substantial funding from its first international investor, Medical Incubator Japan (MIJ). 
• Japan is the third largest healthcare market in the world, and this partnership will enable ILC Therapeutics to access and establish itself within this market going forward
• This investment comes at a time when ILC Therapeutics is receiving growing recognition as a key player in modulating the Innate Immune System.

UK-based biotechnology company ILC Therapeutics (ILCT) today announced that it has secured significant investment from its first global investor Medical Incubator Japan (MIJ).

The Scottish life sciences company, which has received international attention through its work exploring COVID-19 therapeutic treatments with the University of St Andrews, is MIJ’s first investment in a biotech company in Europe.

The core patented science of the company, developed by founder and chief scientific officer Prof. William H. Stimson FRSE, is based on the modulation of the human Innate Immune System through its own synthetic Hybrid Interferons.

The Innate Immune System is involved in a number of diseases: atopic dermatitis, psoriasis, qsthma, gut inflammatory disorders, Alzheimer’s disease, cancer and is vital for fighting viral infections like COVID-19.

Initial findings from the company’s research with the University of St Andrews showed its unique synthetic Interferon, Alfacyte™, is 15 to 20 times more effective than other commercially available interferons at killing and inhibiting SARS-CoV-2 (the virus which causes COVID-19) in vitro.

The company is now working towards clinical trials in order to bring this treatment to market.

Medical Incubator Japan is an independent healthcare-focused venture capital company aimed at investing in early-stage life sciences companies across a broad range of innovations including drug discovery, digital health and medical devices.

Its second fund launched in the summer of 2020, focusing on investments both in Japan and overseas. Through its partnership with Bamburgh Capital, MIJ is particularly focused on identifying investment opportunities in the UK, where MIJ is attracted by the compelling opportunities to invest in innovative companies opening up world-class science and supported by collaborative, informed and influential ecosystems.

Japan is the third largest healthcare market in the world and MIJ will be able to help ILCT access this important market.

MIJ President Jun Katsura said: “We are delighted that ILC Therapeutics is the first investment of our second fund and our first investment in the UK.

“We are off to a good start with ILCT because its novel interferon technology has great potential to develop effective treatments for SARS-CoV-2 as well as for other viral diseases, immune diseases and cancer.

“We strongly believe they can provide long-awaited solutions in such an intractable disease area and we are very excited to be part of their journey.”

Dr Alan Walker, Chief Executive Officer at ILC Therapeutics, added: “This latest investment from MIJ demonstrates the growing recognition of ILC Therapeutics as a global leader in modulating the Innate Immune System, and we are thrilled to have them aboard.

“We feel hugely positive about this next chapter in ILC Therapeutics’ development.”

MIJ joins an existing cohort of investors which include Scottish Enterprise and St Andrews-based investment syndicate EOS Advisory, which is the company’s first and largest investor.

This media release generated the following coverage:

The Pharma Letter

Bloomberg

AsianPolyGlotView